Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALSMichael Benatar, G. Garcia Gutierrez, Ted M. Burns et al.|Neurology|2020Cited by 201
Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysisMichael Benatar, Eric A. Macklin, Andrea Malaspina et al.|EBioMedicine|2024Cited by 43
Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): a national, cross-sectional studyChristine Zizzi, Chad Heatwole, Jamison Seabury et al.|EClinicalMedicine|2022Cited by 29
Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosisKaterina Placek, Corey T. McMillan, Michael Benatar et al.|EMBO Molecular Medicine|2020Cited by 27
Pridopidine in Amyotrophic Lateral SclerosisPiera Pasinelli, Po-Ying Lai, H.Y. Chen et al.|JAMA|2025Cited by 17